JP2011500673A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011500673A5 JP2011500673A5 JP2010529900A JP2010529900A JP2011500673A5 JP 2011500673 A5 JP2011500673 A5 JP 2011500673A5 JP 2010529900 A JP2010529900 A JP 2010529900A JP 2010529900 A JP2010529900 A JP 2010529900A JP 2011500673 A5 JP2011500673 A5 JP 2011500673A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- methylphenyl
- disorder
- tetrazol
- triazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 19
- 208000035475 disorder Diseases 0.000 claims description 17
- 208000002193 Pain Diseases 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 102000012777 Metabotropic Glutamate 5 Receptor Human genes 0.000 claims description 3
- 108010065028 Metabotropic Glutamate 5 Receptor Proteins 0.000 claims description 3
- 206010015037 epilepsy Diseases 0.000 claims description 3
- 230000001404 mediated effect Effects 0.000 claims description 3
- 206010019196 Head injury Diseases 0.000 claims description 2
- 208000013016 Hypoglycemia Diseases 0.000 claims description 2
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 7
- -1 3-methylphenyl-2H-tetrazol-5-yl Chemical group 0.000 claims 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- 208000019695 Migraine disease Diseases 0.000 claims 3
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims 3
- 206010027599 migraine Diseases 0.000 claims 3
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 206010012335 Dependence Diseases 0.000 claims 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 208000004296 neuralgia Diseases 0.000 claims 2
- 208000021722 neuropathic pain Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 2
- NQBOKVREWGZKJU-MRVPVSSYSA-N (1r)-1-[2-(3-methylphenyl)tetrazol-5-yl]ethanol Chemical compound N1=C([C@H](O)C)N=NN1C1=CC=CC(C)=C1 NQBOKVREWGZKJU-MRVPVSSYSA-N 0.000 claims 1
- MBVZOUHNLPNTLU-UHFFFAOYSA-N 1-[2-(3-methylphenyl)tetrazol-5-yl]ethanone Chemical compound N1=C(C(=O)C)N=NN1C1=CC=CC(C)=C1 MBVZOUHNLPNTLU-UHFFFAOYSA-N 0.000 claims 1
- VLDOGHBCDVMKJO-UHFFFAOYSA-N 2-(4-methyl-5-methylsulfanyl-1,2,4-triazol-3-yl)pyrimidine Chemical compound CN1C(SC)=NN=C1C1=NC=CC=N1 VLDOGHBCDVMKJO-UHFFFAOYSA-N 0.000 claims 1
- RVJAQHSUJLBQMF-UHFFFAOYSA-N 2-(4-methyl-5-methylsulfonyl-1,2,4-triazol-3-yl)pyrimidine Chemical compound N1=C(S(C)(=O)=O)N(C)C(C=2N=CC=CN=2)=N1 RVJAQHSUJLBQMF-UHFFFAOYSA-N 0.000 claims 1
- OOWUAHYPZKCHLH-GFCCVEGCSA-N 2-[4-methyl-5-[(1r)-1-[2-(3-methylphenyl)tetrazol-5-yl]ethoxy]-1,2,4-triazol-3-yl]pyrimidine Chemical compound O([C@H](C)C1=NN(N=N1)C=1C=C(C)C=CC=1)C(N1C)=NN=C1C1=NC=CC=N1 OOWUAHYPZKCHLH-GFCCVEGCSA-N 0.000 claims 1
- OXWBQROFVREADY-UHFFFAOYSA-N 2-methyl-4-(4-methyl-5-methylsulfanyl-1,2,4-triazol-3-yl)pyridine Chemical compound CN1C(SC)=NN=C1C1=CC=NC(C)=C1 OXWBQROFVREADY-UHFFFAOYSA-N 0.000 claims 1
- ZPVFNNAJFOSGQA-CQSZACIVSA-N 2-methyl-4-[4-methyl-5-[(1r)-1-[2-(3-methylphenyl)tetrazol-5-yl]ethoxy]-1,2,4-triazol-3-yl]pyridine Chemical compound O([C@H](C)C1=NN(N=N1)C=1C=C(C)C=CC=1)C(N1C)=NN=C1C1=CC=NC(C)=C1 ZPVFNNAJFOSGQA-CQSZACIVSA-N 0.000 claims 1
- UQAZCZQPTDHGBU-UHFFFAOYSA-N 2-methyl-5-(4-methyl-5-methylsulfanyl-1,2,4-triazol-3-yl)pyrazine Chemical compound CN1C(SC)=NN=C1C1=CN=C(C)C=N1 UQAZCZQPTDHGBU-UHFFFAOYSA-N 0.000 claims 1
- QFHRESWLTOSUJH-UHFFFAOYSA-N 2-methyl-5-(4-methyl-5-methylsulfonyl-1,2,4-triazol-3-yl)pyrazine Chemical compound C1=NC(C)=CN=C1C1=NN=C(S(C)(=O)=O)N1C QFHRESWLTOSUJH-UHFFFAOYSA-N 0.000 claims 1
- OCIUHGHSQQFGAU-CYBMUJFWSA-N 2-methyl-5-[4-methyl-5-[(1r)-1-[2-(3-methylphenyl)tetrazol-5-yl]ethoxy]-1,2,4-triazol-3-yl]pyrazine Chemical compound O([C@H](C)C1=NN(N=N1)C=1C=C(C)C=CC=1)C(N1C)=NN=C1C1=CN=C(C)C=N1 OCIUHGHSQQFGAU-CYBMUJFWSA-N 0.000 claims 1
- YOKDBPXYKWEEFJ-UHFFFAOYSA-N 5-(4-methyl-5-methylsulfanyl-1,2,4-triazol-3-yl)pyrimidine Chemical compound CN1C(SC)=NN=C1C1=CN=CN=C1 YOKDBPXYKWEEFJ-UHFFFAOYSA-N 0.000 claims 1
- YOLMBYXXELXYKV-UHFFFAOYSA-N 5-(4-methyl-5-methylsulfonyl-1,2,4-triazol-3-yl)pyrimidine Chemical compound N1=C(S(C)(=O)=O)N(C)C(C=2C=NC=NC=2)=N1 YOLMBYXXELXYKV-UHFFFAOYSA-N 0.000 claims 1
- WLXQXSOPLQNURC-GFCCVEGCSA-N 5-[4-methyl-5-[(1r)-1-[2-(3-methylphenyl)tetrazol-5-yl]ethoxy]-1,2,4-triazol-3-yl]pyrimidine Chemical compound O([C@H](C)C1=NN(N=N1)C=1C=C(C)C=CC=1)C(N1C)=NN=C1C1=CN=CN=C1 WLXQXSOPLQNURC-GFCCVEGCSA-N 0.000 claims 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000004998 Abdominal Pain Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 208000019984 Auditory nerve disease Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 208000008035 Back Pain Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 208000002881 Colic Diseases 0.000 claims 1
- 206010011224 Cough Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 208000008930 Low Back Pain Diseases 0.000 claims 1
- 206010026749 Mania Diseases 0.000 claims 1
- 208000036626 Mental retardation Diseases 0.000 claims 1
- 206010029148 Nephrolithiasis Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims 1
- 208000004550 Postoperative Pain Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- 208000027520 Somatoform disease Diseases 0.000 claims 1
- 208000009205 Tinnitus Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 235000019788 craving Nutrition 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000006549 dyspepsia Diseases 0.000 claims 1
- MHZNJJVWSPDLCW-UHFFFAOYSA-N ethyl 2-(3-methylphenyl)tetrazole-5-carboxylate Chemical compound N1=C(C(=O)OCC)N=NN1C1=CC=CC(C)=C1 MHZNJJVWSPDLCW-UHFFFAOYSA-N 0.000 claims 1
- 208000001130 gallstones Diseases 0.000 claims 1
- 125000005638 hydrazono group Chemical group 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 208000037906 ischaemic injury Diseases 0.000 claims 1
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000005906 menstruation Effects 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 230000004766 neurogenesis Effects 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 208000027753 pain disease Diseases 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 231100000886 tinnitus Toxicity 0.000 claims 1
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 description 3
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 description 3
- 229930195712 glutamate Natural products 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 230000005284 excitation Effects 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- 230000035778 pathophysiological process Effects 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98129407P | 2007-10-19 | 2007-10-19 | |
| PCT/SE2008/051170 WO2009051556A1 (en) | 2007-10-19 | 2008-10-17 | Tetrazole derivatives as modulators of metabotropic glutamate receptors (mglurs) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011500673A JP2011500673A (ja) | 2011-01-06 |
| JP2011500673A5 true JP2011500673A5 (enExample) | 2011-11-24 |
Family
ID=40567640
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010529900A Pending JP2011500673A (ja) | 2007-10-19 | 2008-10-17 | 代謝調節型グルタミン酸受容体（ｍｇｌｕｒｓ）の調節因子としてのテトラゾール誘導体 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US7960422B2 (enExample) |
| EP (1) | EP2231647A4 (enExample) |
| JP (1) | JP2011500673A (enExample) |
| KR (1) | KR20100090777A (enExample) |
| CN (1) | CN101896480A (enExample) |
| AR (1) | AR068921A1 (enExample) |
| AU (1) | AU2008312055A1 (enExample) |
| BR (1) | BRPI0818448A2 (enExample) |
| CA (1) | CA2703425A1 (enExample) |
| CL (1) | CL2008003085A1 (enExample) |
| CO (1) | CO6321281A2 (enExample) |
| CR (1) | CR11376A (enExample) |
| DO (1) | DOP2010000119A (enExample) |
| EA (1) | EA201000654A1 (enExample) |
| IL (1) | IL204958A0 (enExample) |
| MX (1) | MX2010004272A (enExample) |
| PE (1) | PE20090875A1 (enExample) |
| TW (1) | TW200934771A (enExample) |
| UY (1) | UY31403A1 (enExample) |
| WO (1) | WO2009051556A1 (enExample) |
| ZA (1) | ZA201002694B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1847543A1 (de) | 2006-04-19 | 2007-10-24 | Boehringer Ingelheim Pharma GmbH & Co. KG | Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen |
| MX2010003346A (es) * | 2007-10-19 | 2010-04-09 | Boehringer Ingelheim Int | Piperazino-dihidrotienopirimidinas sustituidas en heterociclo. |
| WO2009050236A1 (de) | 2007-10-19 | 2009-04-23 | Boehringer Ingelheim International Gmbh | Neue piperazino-dihydrothienopyrimidin-derivate |
| WO2009050248A1 (de) | 2007-10-19 | 2009-04-23 | Boehringer Ingelheim International Gmbh | Substituierte piperidino-dihydrothienopyrimidine |
| US8536185B2 (en) * | 2008-09-22 | 2013-09-17 | Cayman Chemical Company, Incorporated | Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases |
| WO2010071559A1 (en) * | 2008-12-18 | 2010-06-24 | Astrazeneca Ab | Processes for the manufacture of 3-{4-methyl-5- [ (ir) -1- (2- (3-methylphenyl) -2h-tetrazol-5-yl) -ethoxy] -4h- [1,2, 4] triazol-3-yl} -pyridine, 4-methyl-3-methylthio-5- (3- pyridyl)-l,2,4-triazole, and (ir) -1- [2- (3-methylphenyl) -2h- tetrazol-5-yl] ethanol |
| US8883827B2 (en) | 2009-06-05 | 2014-11-11 | Oslo University Hospital Hf | Azole derivatives as WTN pathway inhibitors |
| CN103429583A (zh) | 2010-12-08 | 2013-12-04 | 奥斯陆大学医院公司 | 作为wnt信号通路抑制剂的三唑衍生物 |
| MX2013010698A (es) | 2011-03-18 | 2014-02-17 | Novartis Ag | Combinaciones de activadores del receptor de acetil-colina nicotinico alfa-7 y antagonistas del receptor de glutamato metabotropico 5 (mglur5) para usarse en la discinesia inducida por dopamina en la enfermedad de parkinson. |
| US9802954B2 (en) | 2011-08-24 | 2017-10-31 | Boehringer Ingelheim International Gmbh | Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma |
| US20130059866A1 (en) | 2011-08-24 | 2013-03-07 | Boehringer Ingelheim International Gmbh | Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma |
| CN106032377A (zh) * | 2015-03-12 | 2016-10-19 | 天津药物研究院有限公司 | 四氮唑类urat1抑制剂、制备方法及其在高尿酸血症和痛风治疗上的用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4663332A (en) * | 1985-10-10 | 1987-05-05 | Hoffman-La Roche Inc. | 5-substituted N-alkylated tetrazoles |
| EP0596933A1 (en) | 1991-08-03 | 1994-05-18 | Smithkline Beecham Plc | 5-ht4 receptor antagonists |
| DE10023430A1 (de) | 2000-05-12 | 2001-11-15 | Bayer Ag | Substituierte N-Benzoyl-N'-(tetrazolylphenyl)-harnstoffe |
| GB0115862D0 (en) | 2001-06-28 | 2001-08-22 | Smithkline Beecham Plc | Compounds |
| GB0121033D0 (en) | 2001-08-30 | 2001-10-24 | Novartis Ag | Organic compounds |
| AU2002341921B2 (en) | 2001-10-04 | 2007-05-31 | Merck Sharp & Dohme Corp. | Heteroaryl substituted tetrazole modulators of metabotropic glutamate receptor-5 |
| WO2003077918A1 (en) | 2002-03-12 | 2003-09-25 | Merck & Co., Inc. | Di-aryl substituted tetrazole modulators of metabotropic glutamate receptor-5 |
| CN1894241A (zh) * | 2002-08-09 | 2007-01-10 | 阿斯利康(瑞典)有限公司 | 作为代谢型谷氨酸受体－5调节剂的“1,2,4” 噁二唑 |
| WO2005077345A1 (en) * | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Compounds for the treatment of gastro-esophageal reflux disease |
| EA200601266A1 (ru) * | 2004-02-18 | 2007-02-27 | Астразенека Аб | Соединения триазола и их применение в качестве антагонистов метаботропного рецептора глутамата |
| JP5084269B2 (ja) | 2004-02-18 | 2012-11-28 | アストラゼネカ アクチボラグ | テトラゾール化合物及び代謝共役型グルタミン酸受容体アンタゴニストとしてのそれらの使用 |
| JP2007523181A (ja) | 2004-02-18 | 2007-08-16 | アストラゼネカ アクチボラグ | ポリヘテロ環式化合物、および、代謝型グルタミン酸受容体アンタゴニストとしてのそれらの使用 |
| US7585881B2 (en) * | 2004-02-18 | 2009-09-08 | Astrazeneca Ab | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| UY29796A1 (es) * | 2005-09-29 | 2007-04-30 | Astrazeneca Ab | Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor |
| TW200811157A (en) | 2006-05-05 | 2008-03-01 | Astrazeneca Ab | mGluR5 modulators I |
| TW200811156A (en) | 2006-05-05 | 2008-03-01 | Astrazeneca Ab | mGluR5 modulators IV |
-
2008
- 2008-10-17 JP JP2010529900A patent/JP2011500673A/ja active Pending
- 2008-10-17 CA CA2703425A patent/CA2703425A1/en not_active Abandoned
- 2008-10-17 EP EP08840285A patent/EP2231647A4/en not_active Withdrawn
- 2008-10-17 WO PCT/SE2008/051170 patent/WO2009051556A1/en not_active Ceased
- 2008-10-17 MX MX2010004272A patent/MX2010004272A/es not_active Application Discontinuation
- 2008-10-17 UY UY31403A patent/UY31403A1/es unknown
- 2008-10-17 US US12/285,988 patent/US7960422B2/en not_active Expired - Fee Related
- 2008-10-17 AR ARP080104548A patent/AR068921A1/es unknown
- 2008-10-17 PE PE2008001783A patent/PE20090875A1/es not_active Application Discontinuation
- 2008-10-17 CN CN2008801179810A patent/CN101896480A/zh active Pending
- 2008-10-17 BR BRPI0818448 patent/BRPI0818448A2/pt not_active IP Right Cessation
- 2008-10-17 AU AU2008312055A patent/AU2008312055A1/en not_active Abandoned
- 2008-10-17 KR KR1020107010834A patent/KR20100090777A/ko not_active Withdrawn
- 2008-10-17 CL CL2008003085A patent/CL2008003085A1/es unknown
- 2008-10-17 EA EA201000654A patent/EA201000654A1/ru unknown
- 2008-10-17 TW TW097139967A patent/TW200934771A/zh unknown
-
2010
- 2010-04-08 IL IL204958A patent/IL204958A0/en unknown
- 2010-04-16 ZA ZA2010/02694A patent/ZA201002694B/en unknown
- 2010-04-19 CR CR11376A patent/CR11376A/es not_active Application Discontinuation
- 2010-04-19 DO DO2010000119A patent/DOP2010000119A/es unknown
- 2010-04-28 CO CO10050285A patent/CO6321281A2/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011500673A5 (enExample) | ||
| JP2009510064A5 (enExample) | ||
| RU2008108219A (ru) | Соединения, представляющие собой 5-(фенилизоксазолилэтокси)-триазол-3-ил-замещенный пиридин, для лечения неврологических, психиатрических или болевыхрасстройств | |
| TWI511728B (zh) | 包含非典型抗精神病藥物及taar1激動劑之醫藥組合 | |
| JP2007523168A5 (enExample) | ||
| HRP20100654T1 (hr) | Dodatni heterociklicki spojevi i njihova upotreba kao antagonista metabotropnih receptora glutamata | |
| CN1151789C (zh) | 芳基(或杂芳基)吡咯基甲醇的衍生物的应用 | |
| US20100234349A1 (en) | Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer | |
| JP2008007519A5 (enExample) | ||
| JP2018518537A5 (enExample) | ||
| JP2013500267A5 (enExample) | ||
| JP2010510202A5 (enExample) | ||
| JP2010526145A5 (enExample) | ||
| JP2020516671A5 (enExample) | ||
| JP2006517939A5 (enExample) | ||
| JP2006513202A5 (enExample) | ||
| JP2012515787A5 (enExample) | ||
| JP2012515788A5 (enExample) | ||
| TW201240661A (en) | Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for lowering intraocular pressure | |
| JP2019512532A5 (enExample) | ||
| JP2006507225A5 (enExample) | ||
| JP2002544178A (ja) | 腎機能障害の治療用の医薬の製造のためのドーパミン−ｄ３−レセプターリガンドの使用 | |
| JP2008508247A5 (enExample) | ||
| JP2013544811A5 (enExample) | ||
| JP2012528824A5 (enExample) |